DAFTAR PUSTAKA
1. Huang DT, et al. Risk Prediction With Procalcitonin and Clinical Rules in
Community-Acquired Pneumonia. Ann Emerg Med. 2008;52:48-58
2. Crain MC, et al. Procalcitonin Guidance of Antibiotic Therapy in
Community-acquired Pneumonia: A Randomized Trial. Am J Respir Crit Care Med.
2006;174:84–93
3. A. Singayanagam JD, Chalmers and Hill AT. Severity assessment in
Community Acquired Pneumonia.Q J Med. 2009; 102:379–388.
4. Summah H, Qu JM. Biomarkers: A Definite Plus in Pneumonia. Mediator of
Inflamation. 2009: 1-9.
5. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Jeune IL, et.al.
British Thoracic Society Guidelines For The Management of Community
Acquired Pneumonia in Adults: update 2009. Thorax. 2009; 64(suppl II):
1-55.
6. Mira JP, Max A, Burgel PR. The role of biomarkers in community-acquired
pneumonia: predicting mortality and response to adjunctive therapy. Critical
Care 2008, 12(Suppl 6):S5
7. Muller B, et al. Diagnostic and prognostic accuracy of clinical and laboratory
parameters in community-acquired pneumonia. BMC Infectious Diseases.
2007; 7:10
8. Kang YA, et al. Role of C-Reactive Protein and Procalcitonin in
Differentiation of Tuberculosis from Bacterial Community Acquired
9. Marrie JT. Acute bronchitis and community acquired pneumonia in Fisman’s
pulmonary disease and disorder. 4th ed. USA. McGraw-Hill companies. 2008;
119: 2097-2114
10.Niederman MS, Biological Markers to Determine Eligibility in Trials for
Community-Acquired Pneumonia: A Focus on Procalcitonin. Clinical
Infectious Diseases 2008; 47:S127–32
11. Situmorang AT. Hubungan Kadar Procalcitonin Saat Awal Masuk Pada
Pasien Dengan Pneumonia Komunitas Terhadap Skor CURB-65. Tesis.
Departemen Penyakit Dalam Fakultas Kedokteran Universitas Sumatera
Utara. Medan. 2012
12.Crain MC, Muller B. Biomarkers in respiratory tract infections: diagnostic
guides to antibiotic prescription, prognostic markers and mediators. Eur
Respir J.2007; 30: 556–573
13.Rumende CM. Procalcitonin dan Lipopolysaccharide-Binding Protein Sebagai
Prediktor dan Petanda Prognostik Ventilator Associated Pneumonia pada
Pasien HCU/ICU RSCM tahun 2006-2007. Diunduh dari :
www.majalah-farmacia.com/rubrik/one-news
14.Murzalina C. Procalcitonin pada pasien sepsis yang telah mendapat perawatan
di ruang rawat intensif. Tesis. Departemen Patologi Klinik Fakultas
Kedokteran Universitas Sumatera Utara. Medan. 2007.
15.Lee JY, et al. Clinical Significance of Serum Procalcitonin in Patients with
Community-acquired Lobar Pneumonia. Korean J Lab Med. 2010;30:406-13
16.Schuetz P, Suter-Widmer I, Chaudri A. Prognostic value of procalcitonin in
17.Kruger S. Procalcitonin predicts patients at low risk of death from
community-acquired pneumonia across all CRB-65 classes. Eur Respir J. 2008; 31: 349–
355
18.Masia M, et al. Usefulness of Procalcitonin Levels in Community-Acquired
Pneumonia According to the Patients Outcome Research Team Pneumonia
Severity Index. CHEST 2005; 128:2223–2229
19.Wibisono M.Yusuf, Winariati, Hariadi Slamet. Buku Ajar Ilmu Penyakit Paru.
Departemen Ilmu Penyakit Paru FK UNAIR-RSUD dr.Soetomo.2010;127-129
20.Perhimpunan Dokter Spesialis Paru Indonesia. Pneumonia Komunitas.
Pedoman diagnosis dan penatalaksanaan di Indonesia.ed II.2014
21.Mandell LA, Wunderink, Richard. Pneumonia in Harrison's Principles of
Internal Medicine. USA. 2008.17th ed.: 1619-1628
22.Rab Tabrani. Ilmu Penyakit Paru. Trans Info Media. 2010: 214-216
23.Tseng JS, Chan MC, Hsu JY, Kuo BIT, Wu CL. Procalcitonin is a Valuable
Prognostic Markers in ARDS caused by Community Acquired Pneumonia.
Respirology. 2008;13: 505-9.
24.Mandell LA, Wunderik RG, Arzueto A, Bartlett JG, Campbell GD, Dean NC,
et.al. Infectious Diseases Society of America/ American Thoracic Society
Consensus Guidelines on The Management of Community Acquired
Pneumonia in Adults. CID. 2007; 44: 27- 72.
25.Buchori, Prihatini. Diagnosis Sepsis menggunakan Procalcitonin.Indonesian
Journal of Clinical Pathology and Medical Laboratory.2006;12(3):131-7
26.Schuetz P, et al. Procalcitonin for diagnosis of infection and guide to antibiotic
27.Ahmed Shah Bashir, et al. Validity of Pneumonia Severity Index and
CURB-65 Severity Scoring Systems in Community Acquired Pneumonia in an Indian
Setting.Indian J Chest Dis Allied Sci. 2010;52:9-17
28.Karlsson Sari, Heikkinen Millja, Pettila Ville, et al. Predictive value of pct
decrease in patients with severe sepsis: a prospective observational studies.
Critical Care 2010; 14:R205.
29.Schuetz P, Christ-Crain M, Muller B. Procalcitonin and other biomarkers to
improve assessment and antibiotic stewardship in infection- hope for hype ?
SWISS MED WKLY. 2009; 139: 318-26.
30.McGee Kristopher A, Baumann Nikola A. Procalcitonin Clinical Utility in
Diagnosing Sepsis. American Association for Clinical Chemistry. 2009:35 - 7
31.Maier M, Wutzler S, Lehnert M, Szermutzky, Hendrik W, Bingold T, et.al.
Serum Procalcitonin Level in Patients with Multiple Injuries Including Viseral
Trauma. Journals of Trauma. 2009; 66: 243-49.
32.Tseng JS, Chan MC, Hsu JY, Kuo BIT, Wu CL. Procalcitonin is a Valuable
Prognostic Markers in ARDS caused by Community Acquired Pneumonia.
Respirology. 2008;13: 505-9.
33.Jung DY, Park JB, Lee EN, Lee HT, Joh JW, Kwon CH, et. al. Combined use
of Myeloid-related protein 8/14 and Procalcitonin as diagnostic markers for
acute allograft rejection in kidney transplantation recipients. Transplant
Immunology. 2008; 18: 338-43.
34.Gilbert DN. Use of Plasma Procalcitonin Levels as an Adjunct to Clinical
35.Bont J, Hak E, Hoes AW, Macfarlane JT, Verheij TJM. Predicting Death in
Elderly Patients with Community Acquired Pneumonia: A Prospective
Validation Study Reevaluating the CRB-65 Severity Assesment Tool. Arch
Intern Med. 2008; 168: 1465
36.Irwin AD, Carrol ED. Procalcitonin. Arch Dis Child Educ Pract Ed . 2011:
228
37.Aabenhus,Rune. Jensen, Jens-Ulrik Stæhr. Procalcitonin-guided antibiotic
treatment of respiratory tract infections in a primary care setting: are we there
yet? Prim Care Respir J. 2011; 20(4): 360-367
38.Nayak SB, Sakhamuri MS, Raghunanan B, Allison A, Uppalapati K, Patcha K.
The role of serum markers in assessing the severity and outcome of community
acquired pneumonia in Trinidadian population. Journal of Public Health and
